Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TO-209 Phase III Trial in Grass Pollinosis
jRCT2041250027Phase 3Active, not recruiting
- Sponsor
- Torii Pharmaceutical
- Start
- Jun 2025
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in grass pollen allergy, seasonal allergic rhinitis (SAR) and allergic conjunctivitis (AC) comparing TO-209 sublingual with Placebo sublingual (2 arms). Started Jun 2025; status: active, not recruiting.
02
Drugs
Timothy grass pollen allergen extract
03
Conditions
grass pollen allergyseasonal allergic rhinitis (SAR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on jRCT2041250027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250027.